%A Joshua D. TOMPKINS,Arthur D. RIGGS %T An epigenetic perspective on the failing heart and pluripotent-derived-cardiomyocytes for cell replacement therapy %0 Journal Article %D 2015 %J Front. Biol. %J Frontiers in Biology %@ 1674-7984 %R 10.1007/s11515-014-1340-0 %P 11-27 %V 10 %N 1 %U {https://journal.hep.com.cn/fib/EN/10.1007/s11515-014-1340-0 %8 2015-02-14 %X

As life expectancy rises, the prevalence of heart failure is steadily increasing, while donors for organ transplantation remain in short supply (Zwi-Dantsis and Gepstein, 2012). Indeed, myocardial infarction represents the foremost cause of death within industrialized nations (Henning, 2011) and further, approximately 1% of all newborns harbor a congenital heart defect. Although medical interventions allow>80% of those with cardiac defects to survive to adulthood, there are often extreme emotional and financial burdens that accompany such congenital anomalies, and many individuals will remain at a heightened risk for myocardial infarction throughout the remainder of their lives (Verheugt et al., 2010; Amianto et al., 2011). In this review, we will discuss the nature of the failing heart and strategies for repair from an epigenetic standpoint. Significant focus will reside on pluripotent-to-cardiomyocyte differentiation for cell replacement, epigenetic mechanisms of cardiomyocyte differentiation, epigenetic “memories,” and epigenetic control of cardiomyocyte cell fate toward translational utility.